KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Raw Materials (2016 - 2024)

Nektar Therapeutics has reported Raw Materials over the past 13 years, most recently at $1.7 million for Q2 2024.

  • Quarterly results put Raw Materials at $1.7 million for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $1.7 million (changed N/A YoY), and the annual figure for FY2023 was $1.9 million, down 27.73%.
  • Raw Materials for Q2 2024 was $1.7 million at Nektar Therapeutics, down from $1.9 million in the prior quarter.
  • Over the last five years, Raw Materials for NKTR hit a ceiling of $2.6 million in Q4 2022 and a floor of $1.7 million in Q2 2024.
  • Median Raw Materials over the past 3 years was $1.9 million (2023), compared with a mean of $2.0 million.
  • Peak annual rise in Raw Materials hit 27.73% in 2023, while the deepest fall reached 27.73% in 2023.
  • Nektar Therapeutics' Raw Materials stood at $2.6 million in 2022, then dropped by 27.73% to $1.9 million in 2023, then dropped by 7.63% to $1.7 million in 2024.
  • The last three reported values for Raw Materials were $1.7 million (Q2 2024), $1.9 million (Q1 2024), and $1.9 million (Q4 2023) per Business Quant data.